Immune response in T1D
Recruiting to: ongoing
Summary
We are inviting people with and without T1D to identify the immune mechanisms that are driven by genome variations that are associated with protection from T1D development in people with and without other diabetes genetic risk factors. We will explore people’s immune cells to see how functional those cells are, and whether there are differences in their phenotype in individuals that have protective genes compared to those that have gene variations that suggest increased risk to T1D development.
Contact us
Call: 020 7594 3735
Email: m.dominguez-villar@imperial.ac.uk
Full Study title: Immunological mechanisms underlying the genetic basis for natural protection from T1D
Eligibility to take part
Patients with T1D
- Confirmed diagnosis of T1D
- No steroids or any immunomodulatory treatments for at least 6 months before blood collection (except for insulin)
- No other autoimmune condition
Unaffected relatives and unrelated subjects
- No history suggestive of T1D or other autoimmune condition
- No other allergic or chronic conditions
- Not on any medication
Exclusion criteria for T1D patients and control subjects
- Other autoimmune or chronic inflammatory or infectious disease
- Individuals unable to understand the purpose and scope of the research
- Individuals unable to retain the information long enough to make an effective decision by themselves
- Individuals under 18 years of age or over 65 years old
- Vulnerable individuals: prisoners, subjects lacking the capacity to consent for themselves
What will I be asked to do?
If you decide to take part, we will invite you to the study centre for a single study visit at a time that is convenient for you. In this visit, we will go through this information sheet and answer any questions you may have before taking your consent for the study. We will then ask a few basic demographic and diabetes questions and take blood sample. We will take around 100 mL of blood (5 tablespoons). The study visit will take around 30-60 minutes.
Who is running this study?
The study is run by Dr Margarita Dominguez-Villar at St Mary’s Campus, Imperial College London. It is funded by Helmsley Charitable Trust and Diabetes UK.
ELSA – EARLY SURVEILLANCE FOR AUTOIMMUNE DIABETES
Recruiting to: ongoing
‘Sooner we screen, sooner we can intervene’
Aim
The ELSA Study is screening children aged from 3-13 years to determine their risk of developing type 1 diabetes.
Who can take part?
ANY child aged 3-13 years who does not currently have type 1 diabetes. There is no need for the child to be from a family where someone has type 1 diabetes – children from any family can be tested.
What does the ELSA study involve?
Parents/guardians willing for their child/ren to take part in the ELSA Study can complete the consent form online or by post. The screening test is a simple finger-stick blood test. The home testing kit is available to families across the United Kingdom and this will be sent by post with instructions and a video of how to perform the test.
For any child found to be at risk of type 1 diabetes in the future, we will invite the family to attend a one-to-one education session to explain what the results mean. We will also refer the family to further research studies their child may be eligible for, including monitoring follow-up and prevention trials.
For more information, please visit our online information tool for parents: https://elsa-info.digitrial.com/get-started
For any queries, please contact the ELSA Study Team:
Online contact form: https://elsadiabetes.nhs.uk/contact-us/
Call: 0121 414 7814 (Monday – Friday, 9-5pm)
Email: elsa@contacts.bham.ac.uk
Who is running this study?
The ELSA study is being run by the University of Birmingham and led by Professor Parth Narendran. The ELSA study is co-funded by Diabetes UK and JDRF.
Recruiting sites
Recruiting nationally via online and postal systems to all eligible families in the UK.
Open to recruitment:
- Birmingham Children’s Hospital
- Birmingham Community Healthcare Trust
- University Hospitals Sussex NHS
- Cambridge Addenbrooks Hospital
- Royal Devon and Exeter Hospital, Exeter
- East Lancashire Royal Blackburn Hospital
- Leeds Children’s Hospital
- Alder Hey Children’s Hospital
- Barts Health NHS Trust
- Royal Free Hospital, London
- Newcastle Royal Victoria Infirmary
- Nottingham Queen’s Medical Centre
- Oxford University Hospital
- University Hospital Southampton
- Surrey and Sussex Healthcare NHS Trust
- Royal Aberdeen Children’s Hospital
- NHS Tayside
- West Glasgow Ambulatory Care Hospital
- Southern Health and Social Care Trust
Opening soon
- Royal Infirmary of Edinburgh
What will I be asked to do?
In the ELSA Study, we are screening children for type 1 diabetes. The study has 5 steps:
- Step 1 – Finger prick blood test to screen for antibodies (20,000 children)
- Step 2 – Venous blood test to test for antibodies (for children who screened positive at stage 1)
- Step 3 – Venous blood tests for staging of type 1 diabetes (for children who tested positive at stage 2)
- Step 4 – Education session (for parents of children at-risk)
- Step 5 – Interviews with parents/guardians to provide feedback on the screening programme
What are we testing for?
In the ELSA study, we are testing for antibodies (protein markers in the blood) because antibodies are markers of risk of type 1 diabetes. There are 4 antibodies we are testing for in the ELSA Study.
As the number of antibodies a child has rises, this increases their risk of developing type 1 diabetes in the future. For example, for children who have 2 of these antibodies, within the next 10 years, 3 in 4 of these children will develop symptoms of type 1 diabetes.
For children who have 1 of these antibodies present, their risk is not as high, but they could develop more antibodies over time.
For children who do not have any of these antibodies, this means they are currently at low risk of developing type 1 diabetes. But, they could still develop antibodies in the future
3 in 1000 children are at high risk of getting type 1 diabetes and we can only find these children by screening.